C4 Therapeutics, Inc.

CCCC

C4 Therapeutics, Inc.

CCCC

Insider Sentiment (TTM):

Last Purchase:2023-02-08Last Sale:2026-01-16Shares Purchased (TTM):0Shares Sold (TTM):10,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:79,077,323Shares Outstanding:126,074,555Institutional Ownership Pct.:62.72%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	79	61	75	59	78	51	55	60	73	90	127	61
Debt Securities Available For Sale Excluding Accru…	175	174	174	133	136	164	189	196	191	169	127	156
Accounts Receivable Net Current	1	3	2	7	2	8	3	10	1	14	12	1
Prepaid Expense And Other Assets Current	8	7	7	8	8	9	10	7	11	8	6	7
Assets Current	263	245	258	207	225	233	258	273	276	280	271	224
Debt Securities Available For Sale Excluding Accru…	47	33	49	8	8	20	22	29	32	41	28	30
Property Plant And Equipment Net	4	4	5	5	6	5	6	6	7	7	7	7
Operating Lease Right Of Use Asset	38	39	41	42	54	56	58	59	61	62	64	66
Restricted Cash And Cash Equivalents Noncurrent	3	3	3	3	3	3	3	3	3	3	3	3
Other Assets Noncurrent	4	4	4	0	0	3	3	5	3	5	3	3
Assets	359	329	359	265	297	320	350	376	381	398	376	333
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	1	1	2	1	1	2	1	2	1	1
Accrued Liabilities And Other Liabilities	14	10	13	11	14	13	19	15	11	13	21	15
Contract With Customer Liability Current	27	10	12	17	23	22	19	21	37	35	15	8
Operating Lease Liability Current	7	7	6	6	6	6	6	6	5	5	5	5
Liabilities Current	48	27	33	36	44	41	45	43	54	55	43	30
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	0	0
Contract With Customer Liability Noncurrent	14	15	16	20	21	25	28	29	17	21	22	20
Operating Lease Liability Noncurrent	50	52	54	55	57	58	60	61	63	64	66	67
Liabilities	112	95	102	111	122	124	134	133	134	140	130	117
Long Term Debt Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,035	998	995	873	860	855	850	841	822	815	775	711
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-787	-764	-739	-718	-686	-660	-634	-599	-574	-557	-528	-494
Stockholders Equity	247	234	257	154	174	195	216	243	247	258	246	216
Liabilities And Stockholders Equity	359	329	359	265	297	320	350	376	381	398	376	333
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	150	150	150	150	150	150	150
Common Stock Shares Issued	123	104	97	74	71	71	71	71	69	69	60	49
Shares Outstanding	123	104	97	74	71	71	71	71	69	69	60	49

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	21.45%	35.65%	9.78%	-	-	-	-	-	-	-	-	-
2025	-16.67%	-6.67%	50.67%	0.78%	-13.57%	-5.04%	13.87%	-10.92%	-9.66%	-2.88%	5.04%	28.06%
2024	-22.48%	-28.37%	0.78%	-0.60%	-4.94%	-4.94%	-20.26%	-25.89%	-26.08%	-18.46%	-51.92%	-46.92%
2023	-	-	-	-	-	-	15.91%	237.88%	347.73%	1.48%	-15.80%	-30.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.45	9.00	7.81	5.76	5.06	5.70	5.71	6.31	5.09	5.08	6.34	7.39
Quick Ratio	5.29	8.75	7.60	5.52	4.87	5.47	5.49	6.14	4.89	4.94	6.21	7.17
Working Capital	214.66M	218.12M	225.08M	170.92M	180.27M	191.72M	212.59M	229.94M	221.84M	224.57M	228.42M	193.42M
Leverage & Debt
Debt to Equity	0.45	0.40	0.40	0.72	0.70	0.64	0.62	0.55	0.54	0.54	0.53	0.54
Debt Ratio	0.31	0.29	0.29	0.42	0.41	0.39	0.38	0.35	0.35	0.35	0.35	0.35
Efficiency & Turnover
Asset Turnover TTM	0.11	0.11	0.10	0.09	0.10	0.11	0.10	0.09	0.08	0.05	0.05	0.05
Days Sales Outstanding TTM	18.19	57.12	27.94	102.34	17.72	99.21	76.42	58.76	13.64	128.68	116.70	17.83
Receivables Turnover TTM	20.07	6.39	13.06	3.57	20.60	3.68	4.78	6.21	26.77	2.84	3.13	20.47
Per Share Metrics
Diluted EPS TTM	-0.78	-0.82	-1.27	-1.64	-1.57	-1.46	-1.52	-1.52	-1.57	-1.84	-2.67	-2.74
Free Cash Flow Per Share TTM	-0.68	-0.76	-1.20	-0.85	-0.77	-1.14	-0.94	-1.03	-1.14	-1.36	-2.19	-2.34
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-318.97%	-326.56%	-320.53%	-431.07%	-361.03%	-292.99%	-336.15%	-354.44%	-404.71%	-673.90%	-669.84%	-687.49%
Net Profit Margin TTM	-289.44%	-297.76%	-292.08%	-395.51%	-325.88%	-259.60%	-295.96%	-313.35%	-367.17%	-629.24%	-638.34%	-663.05%
Growth Metrics
Net Revenue Growth (1Y)	2.33%	-12.37%	1.02%	-10.57%	16.55%	98.56%	71.44%	65.45%	83.26%	-26.34%	-33.25%	-63.50%
Net Income Growth (1Y)	-9.11%	0.51%	-0.31%	12.88%	3.44%	-18.08%	-20.51%	-21.81%	-22.87%	-4.01%	3.37%	26.51%
EPS Growth (1Y)	-50.62%	-43.53%	-16.57%	8.31%	0.24%	-20.86%	-43.12%	-44.74%	-45.00%	-31.22%	1.75%	25.77%
Valuation Metrics
P/E TTM	-6.02	-3.19	-1.51	-1.35	-0.91	-1.10	-2.37	-3.76	-2.95	-4.43	-2.12	-0.68
P/B TTM	2.47	1.42	0.62	1.04	0.58	0.58	1.16	1.64	1.29	2.16	1.14	0.42
P/S TTM	17.42	9.51	4.40	5.35	2.97	2.85	7.02	11.79	10.82	27.90	13.51	4.50
Market Cap	610.35M	331.58M	158.33M	161.09M	101.54M	113.33M	249.74M	396.87M	317.90M	559.09M	280.47M	91.53M
Enterprise Value	531.74M	270.30M	83.73M	102.28M	19.94M	62.04M	190.80M	333.78M	244.79M	469.43M	153.88M	30.56M
Calculated Values
Free Cash Flow TTM	-88.72M	-96.02M	-99.30M	-61.80M	-54.32M	-80.54M	-65.37M	-71.60M	-78.76M	-92.95M	-108.55M	-115.00M
Net Debt	-78.61M	-61.27M	-74.60M	-58.81M	-81.60M	-51.29M	-58.94M	-63.09M	-73.11M	-89.66M	-126.59M	-60.97M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-16Sale

Owner: Reyno, Leonard

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $2.22

Value: $22,200.00

Shares Owned: 156,382

Relationship: Officer

Ownership: Direct

2025-02-18Sale

Owner: Boyle, Scott N

Title: Chief Business Officer

Shares: 669

Price/Share: $3.15

Value: $2,107.35

Shares Owned: 107,805

Relationship: Officer

Ownership: Direct

2023-02-08Purchase

Owner: Koppikar, Utpal

Title: -

Shares: 5,667

Price/Share: $5.60

Value: $31,735.20

Shares Owned: 5,667

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-16	Reyno, Leonard	Officer	Chief Medical Officer	Direct	Sale	10,000	2.22	$22,200.00	156,382	4
2025-02-18	Boyle, Scott N	Officer	Chief Business Officer	Direct	Sale	669	3.15	$2,107.35	107,805	4
2023-02-08	Koppikar, Utpal	Director	-	Direct	Purchase	5,667	5.60	$31,735.20	5,667	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

62.72%

Inst. Shares: 79,077,323

Shares Outstanding: 126,074,555

2025-12-31

95.44%

Inst. Shares: 79,113,431

Shares Outstanding: 82,894,459

2025-09-30

71.91%

Inst. Shares: 52,182,674

Shares Outstanding: 72,563,311

2025-06-30

76.52%

Inst. Shares: 54,332,120

Shares Outstanding: 71,005,743

2025-03-31

89.50%

Inst. Shares: 63,394,208

Shares Outstanding: 70,833,044

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	79,077,323	126,074,555	62.72%
2025-12-31	79,113,431	82,894,459	95.44%
2025-09-30	52,182,674	72,563,311	71.91%
2025-06-30	54,332,120	71,005,743	76.52%
2025-03-31	63,394,208	70,833,044	89.50%
2024-12-31	64,044,134	69,372,993	92.32%
2024-09-30	63,066,650	69,627,190	90.58%
2024-06-30	60,130,173	68,810,259	87.39%
2024-03-31	54,985,959	68,432,168	80.35%
2023-12-31	43,414,682	49,640,505	87.46%
2023-09-30	31,736,127	49,212,126	64.49%
2023-06-30	29,980,830	49,063,631	61.11%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

C4 Therapeutics, Inc. (CCCC) — SEC Financial Statements & Analysis

C4 Therapeutics, Inc. (CCCC) is a biological products, (no diagnostic substances) company, incorporated in DE. C4 Therapeutics, Inc. trades on Nasdaq as: CCCC. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), C4 Therapeutics, Inc. reported a 2.33% year-over-year revenue growth, a Debt-to-Equity ratio of 0.45x, a Price-to-Sales (P/S) ratio of 17.42x (TTM), a Price-to-Book (P/B) ratio of 2.47x (TTM), at a market cap of $610.35M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 2.33%
Debt To Equity: 0.45x
P/S TTM: 17.42x
P/B TTM: 2.47x
Market Cap: $610.35M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is C4 Therapeutics, Inc. in?

C4 Therapeutics, Inc. (CCCC) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CCCC's market cap?

C4 Therapeutics, Inc. (CCCC) has a market capitalization of $610.35M as of 2026-06-30.

What exchange does CCCC trade on?

C4 Therapeutics, Inc. (CCCC) trades on the Nasdaq.

Where is C4 Therapeutics, Inc. incorporated?

C4 Therapeutics, Inc. is incorporated in DE.